Press Releases Transgene

Equities

TNG

FR0005175080

Market Closed - Euronext Paris Other stock markets 11:35:27 2024-04-26 am EDT			5-day change	1st Jan Change
1.21 ^EUR	-5.47%		-12.45%	-11.68%

Apr. 10	Transgene: presents vaccine results at AACR	CF
Mar. 28	Transgene CFO Steps Down; Successor Assumes Office	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024	Apr. 24	GL
Availability of Transgene's 2023 Universal Registration Document	Apr. 11	GL
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024	Apr. 09	GL
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025	Mar. 27	GL
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer	Mar. 27	GL
Transgene Announces Upcoming Investor Meetings	Mar. 18	GL
Transgene Announces Upcoming Investor Meetings	Mar. 18	AQ
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	Mar. 06	GL
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	Mar. 06	AQ
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	Mar. 05	BU
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	Mar. 05	GL
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer	Jan. 22	GL
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer	Jan. 22	AQ
Transgene Announces Financial Calendar for 2024	Jan. 22	GL
Transgene Announces Financial Calendar for 2024	Jan. 22	AQ
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050	Jan. 08	GL
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050	Jan. 08	AQ
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023	Jan. 04	GL
Transgene announces its next meetings with investors	Dec. 22	AQ
BioInvent and Transgene, First patient treated in Part B of Phase 1 trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA	23-10-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Transgene

Equities

TNG

FR0005175080

Press Releases

Filters